Combined Oral Contraceptive Pill and Resistance Starch

NCT ID: NCT06852365

Last Updated: 2025-06-15

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-06-10
• Study Completion Date: 2028-04-30

Brief Summary

This study will enroll women with PCOS to study the effects of first line therapy, oral contraceptive pills, and then either 12 weeks of resistant starch or 12 weeks of placebo to explore if resistant starch improves cardiometabolic parameters or impacts gut dysbiosis compared to placebo.

Conditions

Metabolic Syndrome; Polycystic Ovary Syndrome

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: QUADRUPLE

Study Groups

Resistant Starch

wheat dextrin

Group Type: ACTIVE_COMPARATOR

wheat dextrin

Intervention Type: DIETARY_SUPPLEMENT

participants will take 15 grams per day for 12 weeks

Oral Contraceptives, Low-Dose

Intervention Type: DRUG

20 micrograms ethinyl estradiol and desogestrel 0.15mg

Placebo

maltodextrin

Group Type: PLACEBO_COMPARATOR

Oral Contraceptives, Low-Dose

Intervention Type: DRUG

20 micrograms ethinyl estradiol and desogestrel 0.15mg

Maltodextrin

Intervention Type: DIETARY_SUPPLEMENT

participants will take 15 grams per day for 12 weeks

Interventions

wheat dextrin

participants will take 15 grams per day for 12 weeks

Intervention Type: DIETARY_SUPPLEMENT

Oral Contraceptives, Low-Dose

20 micrograms ethinyl estradiol and desogestrel 0.15mg

Intervention Type: DRUG

Maltodextrin

participants will take 15 grams per day for 12 weeks

Intervention Type: DIETARY_SUPPLEMENT

Other Intervention Names

Benefiber

Eligibility Criteria

Inclusion Criteria

1. Women between ages of 18-40 years with BMI greater than or equal to 25 kg/m² to less than or equal to 48 kg/m² diagnosed with PCOS defined by the Rotterdam criteria based on a history of chronic anovulation (8 or fewer periods), androgen excess [defined as total serum testosterone, free testosterone or a FAI greater than or equal to 90% of the upper limit of normal) or hirsutism (Ferriman-Gallwey score greater than 6 for Hispanics/ Black and greater than or equal to 2 for women of Asian descent)] and polycystic ovaries as defined by a pelvic ultrasound (20 or more follicles or ovarian vol greater than 10cm3) or elevated AMH.

2. For women with more regular bleeding patterns, but who are suspected to be experiencing periodic anovulatory bleeding, a midluteal progesterone (P4) level less than 3ng/dL will be evidence of ovulatory dysfunction and qualify as anovulation.

3. Women with only hyperandrogenic PCOS phenotype (hyperandrogenism + one more criteria) will be included to decrease the heterogeneity of the cohort and as metabolic risks are increased in these women compared to normo-androgenic women with PCOS.

4. Subjects should be willing to avoid pregnancy for the entire duration of the study.

Exclusion Criteria

1. Subjects with other causes for irregular menses such as pregnancy, lactation, untreated hypothyroidism, untreated hyperprolactinemia and premature menopause.

2. Subjects with late onset adrenal hyperplasia

3. Subjects with history of bariatric surgery

4. Those who are unable to comply with the study procedures, for instance due to mental illness, substance abuse, or participation in other studies.

5. Subjects taking medications that affect weight or metabolic parameters (e.g. lipid lowering medications).

6. History of Crohn's disease and ulcerative colitis as well as current use of probiotics and laxatives are excluded.

7. Subjects could not have taken antibiotics for at least 3 months prior to randomization visit.

8. Subjects with greater than 20 g/day of dietary fiber intake based on pre-screening ASA-24 survey will be excluded.

9. Subjects with medical conditions that are contraindications to use of OCP and other medical conditions such as:

1. Type 1 or 2 diabetes

2. liver disease or dysfunctional liver (AST/ALT greater than 2x normal or a total bilirubin greater than 2.5 mg/dL)

3. renal disease (BUN greater than 30 mg/dL or serum creatinine greater than 1.4 mg/dL)

4. severe anemia (hemoglobin less than 10 mg/dL)

5. alcohol abuse

6. poorly controlled hypertension

7. TG greater than 250 mg/dl

8. chronic inflammatory conditions such as psoriasis

9. history of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident; known heart disease (New York Heart Association Class II or higher)

10. history of cervical carcinoma, endometrial carcinoma, or breast carcinoma, adrenal or ovarian tumor secreting androgens, and Cushing's syndrome -

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role: collaborator

University of Pennsylvania

OTHER

Sponsor Role: lead

Responsible Party

Anuja Dokras

Founder's Professor in Women's Health

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Anuja Dokras, MD PhD

Role: CONTACT

adokras@pennmedicine.upenn.edu

215-615-0085

Andrea Morley

Role: CONTACT

andrea.morley@pennmedicine.upenn.edu

215-615-4202

Facility Contacts

Anuja Dokras, MD PhD

Role: primary

Andrea Morley

Role: backup

andrea.morley@pennmedicine.upenn.edu

215-615-4202

Other Identifiers

1R01HL173772-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

856886

Identifier Type: -

Identifier Source: org_study_id